Since we show via IHC that MCL1 and Bcl-xL are co-expressed at high levels in late-stage CRC patient samples, these data highlight a synthetic lethality between DNA damaging agents and Bcl-xL selective inhibitors that could be exploited for therapeutic benefit in this genomic defined and high-risk solid tumor population. The gene discussed is MCL1; the disease is colorectal carcinoma.